TickerJAZZ
SectorBiotechnology
Mkt cap$14.2B
EV / EBITDA33.9×
PostureHigh Velocity
Composite78/100
LensBuyer-side

SE-Cluster Research·Issuer Brief·Q2 2026CIK 1232524

Jazz Pharmaceuticals plc

JAZZHIGH VELOCITYFILING INTENSITY

Jazz Pharmaceuticals plc reads as an High Velocity (composite 78/100); Transformational Buyer deploying $944M across 1 disclosed transactions, down 86% vs the prior cycle · primary market Healthcare.

Lens

Disclosed M&A capital (2023–2025)

$944M

−86%

vs $6.6B in 2020–2022

Disclosed transactions

−50%

1/3 active fiscal years in window

Buyer archetype

Transformational Buyer

Episodic but very large disclosed transactions drive the profile.

Composite score

/100

High Velocity dominates · Filing Intensity

Financial snapshotRevenue$4.4B
EBITDA$395M
Enterprise value$13.4B
EV / Revenue3.0×
EV / EBITDA33.9×
P/EN/A
Cash$1.8B
Total debt$5.4B
as of 2026-05-10

§ I·SE-Cluster Issuer Brief

Behavioral posture, nine reads.

Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.

Active Acquirer

53/100

Companies actively deploying disclosed capital into M&A

$10.7B disclosed buyer spend
Filed within 21d

Buyer Cadence

28/100

Buyer-side companies with recent filing activity

Filed within 21d
266 8-Ks

Target Probability

24/100

Issuers showing target-side patterns from filings

15 activism filings

Spin/Carve

0/100

Issuers showing spin-off, carve-out, or sum-of-parts posture

15 activism filings

Pressure Watch

19/100

Issuers facing activism, governance, or control pressure

15 activism filings
Latest activism 12y ago; heavily discounted

Distress Watch

18/100

Issuers showing financial-distress filing patterns

15 activism filings

Restatement Risk

0/100

Issuers with accounting-integrity flags from filings

1 auditor change
Latest event 14y ago; heavily discounted

Capital Velocity

Dominant

78/100

Issuers with the highest filing-activity intensity

266 8-Ks
Filed within 21d
5 form types

Quiet Power

0/100

Large issuers with low signal volume and clean disclosure cadence

Enterprise value $13.4B
10-Q 21d ago
3 active signals

§ II·SE-Cluster Issuer Brief

Capital cadence.

Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.

Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $6,579M · Peak count: 2

FY	Disclosed buys	Disclosed spend	Avg ticket	Audited tier
2025	1	$944M	$944M	N/A
2024	N/A	N/A	N/A	N/A
2023	N/A	N/A	N/A	N/A
2022	N/A	N/A	N/A	N/A
2021	1	$6.6B	$6.6B	N/A
2020	1	N/A	N/A	N/A

§ III·SE-Cluster Issuer Brief

Strategy posture.

The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.

Archetype mix

Platform
25%
Bolt On
25%
Geographic Expansion
25%
Horizontal Consolidation
25%

Strategy keywords

Terms recurring across recent 10-K acquisition disclosures.

platform
bolt_on
geographic_expansion
horizontal_consolidation

§ IV·SE-Cluster Issuer Brief

Filing language.

Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.

“We acquired worldwide development, manufacturing and commercial rights to JZP-110 from Aerial BioPharma LLC, or Aerial, in January 2014, other than in certain jurisdictions in Asia where SK Biopharmaceuticals Co., Ltd, or SK, retains rights.”

10-KFY2015

“The GW Acquisition was accounted for as a business combination using the acquisition method under which assets and liabilities of GW were recorded at their respective estimated fair values as of the Closing Date”

10-KFY2021

“actively seeking to expand our commercial portfolio through a combination of launching internally developed therapies and commercial assets or investigational therapies acquired through corporate development”

10-KFY2025

“We acquired GW with the objective of broadening our neuroscience portfolio, further diversifying our revenue and driving sustainable, long-term value creation opportunities.”

10-KFY2021

“In 2020, consistent with our strategy, we continued to focus on research and development activities within our neuroscience and oncology therapeutic areas, such as our expansion into movement disorders and solid tumors, and exploring and investing in adjacent therapeutic areas that could further diversify our portfolio, such as post-traumatic stress disorders through our acquisition of SpringWorks Therapeutics, Inc.’s, fatty acid amide hydrolase, or FAAH, inhibitor program.”

10-KFY2020

§ V·SE-Cluster Issuer Brief

Market context.

Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.

Primary market

Healthcare

Market spend (2023–2025): $195B
Market spend (2020–2022): $253.6B
Recent vs prior: −23%
Issuer rank in market: N/A
Share of market capital: 0.0%

Valuation positioning

33.9×EV / EBITDA

JAZZ trades at a +21.0-turn premium to the Healthcare peer median of 12.9×.

EV / Revenue: 3.0×
Net debt / EBITDA: 8.9×
Peer median EV / EBITDA: 12.9×

Trading comparables

FMP market data · 2026-05-10

Company	EV / EBITDA	EV / Rev	Net debt / EBITDA	Revenue	M&A 2023–2025
Jazz Pharmaceuticals plcJAZZ	33.9×	3.0×	8.9×	$4.4B	$944M
AbbVie Inc.ABBV	23.4×	6.7×	3.1×	$62.8B	$18B
UnitedHealth Group IncorporatedUNH	17.2×	0.9×	1.9×	$449.7B	$28.1B
Amgen Inc.AMGN	12.9×	6.0×	2.6×	$37.2B	$26.7B
Elevance Health, Inc.ELV	11.7×	0.5×	2.5×	$200.4B	$6.4B
HCA Healthcare, Inc.HCA	9.3×	1.9×	2.8×	$76.4B	$1.3B

Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.

§ VI·SE-Cluster Issuer Brief

Target landscape.

Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.

No qualifying public-issuer targets surfaced from the current signal mix.

Stated target categories

No target categories enumerated in the audited corpus for this issuer.

§ VII·SE-Cluster Issuer Brief

Filing activity & signal stream.

Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.

Filing cadence

10-K (annual)372026-04-24
10-Q (quarterly)582026-05-05
8-K (event)2662026-05-05
Proxy / DEF 14A682025-07-14
Activism (13D / DFAN / PREC)152014-06-20

Signals on file

elevated
Auditor change
2012-02-28
1 Item 4.01 filing on file; certifying accountant change.
elevated
Activism on file
2014-06-20
15 activist filings on file (13D, DFAN14A, PREC14A series).
info
Signal
Serial acquisition history
info
Signal
10-K strategy themes
info
Signal
Restatement risk

§ VIII·SE-Cluster Issuer Brief

Audited corpus.

No audited record on file for this CIK in the current v6 corpus.

This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.

Search